Shares of Chelsea Therapeutics International Ltd. (CHTP stock quote symbol) closed the week at $5.06 per share after gaining 22.82% on Friday.
CHTP stock has moved dramatically in the past month amid news of a mid-stage trial for a potential chronic-fatigue treatment and FDA approval to start a Phase II trial for its rheumatoid arthritis treatment.
NORTHERA(TM) (droxidopa) is currently Chelsea Therapeutics most advanced drug candidate. NORTHERA(TM) (droxidopa) is an orally active synthetic precursor of norepinephrine which is initially being developed for the treatment of neurogenic orthostatic hypotension.
CHTP stock price quote Chelsea Therapeutics
